The past decade has seen an increasing focus on chronic kidney disease (CKD) and its attendant complications, which has resulted in improved understanding of their impact on health-care resources. The early detection of CKD has been facilitated by the implementation of routine reporting of estimated glomerular filtration rates (eGFRs) and by education of primary care physicians on the implications of detecting a decreased eGFR with respect to patient safety as well as to cardiovascular and renal outcomes. The goals of early CKD detection are to prevent CKD progression and associated complications, thus improving patient outcomes and reducing the impact of CKD on health-care resources. This Review examines the benefits of the early detection of CKD, and describes the limitations of current knowledge with respect to screening, early detection and treatment, as well as the unintended consequences of detection. In addition, this article highlights what is currently known about cardiovascular and renal outcomes and the effects of intervention in patients with CKD.
Chronic kidney disease (CKD) is prevalent worldwide and occurs in conjunction with cardiovascular disease and diabetes
CKD should be defined in terms of both estimated glomerular filtration rates and albuminuria, as each is an independent predictor of prognosis with respect to renal and cardiovascular outcomes
Early detection of CKD allows implementation of treatments and strategies that can influence both progression of kidney disease and cardiovascular health
Detection and identification of CKD facilitates avoidance of drugs and situations that may cause worsening of kidney function and acute kidney injury
CKD is recognized to have widely varying outcomes, which makes predicting the prognosis of individual patients difficult
Improved prediction of renal and other risks in patients with CKD is a focus for research
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
White, S. L., Chadban, S. J., Jan, S., Chapman, J. R. & Cassa, A. How can we achieve global equity in provision of renal replacement therapy? Bull. World Health Organ. 86, 229–237 (2008).
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 39 (2 Suppl. 1), S1–S266 (2002).
National Collaborating Centre for Chronic Conditions. Chronic kidney disease: national clinical guideline for early identification and management in adults in primary and secondary care [online], (2008).
Wilson, J. & Junger, G. Public health papers No. 34: Principles and practice of screening for disease (WHO, Geneva, 1968).
McLaughlin, K., Manns, B., Culleton, B., Donaldson, C. & Taub, K. An economic evaluation of early versus late referral of patients with progressive renal insufficiency. Am. J. Kidney Dis. 38, 1122–1128 (2001).
Boulware, L. E., Jaar, B. G., Tarver-Carr, M. E., Brancati, F. L. & Powe, N. R. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA 290, 3101–3114 (2003).
Atthobari, J. et al. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT). Clin. Ther. 28, 432–444 (2006).
Kidney Health Australia. Cost-effectiveness of early detection and intervention to prevent the progression of chronic kidney disease in Australia [online], (2006).
Klebe, B. et al. The cost of implementing UK guidelines for the management of chronic kidney disease. Nephrol. Dial. Transplant. 22, 2504–2512 (2007).
National Institute for Health and Clinical Excellence. Chronic kidney disease: costing report [online], (2008).
Khan, S. & Amedia C. A. Jr. Economic burden of chronic kidney disease. J. Eval. Clin. Pract. 14, 422–434 (2008).
Black, C. et al. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis. Health Technol. Assess. 14, 1–184 (2010).
Stevens, P. E. & O'Donoghue, D. J. The UK model for system redesign and chronic kidney disease services. Semin. Nephrol. 29, 475–482 (2009).
Wyatt, C., Konduri, V., Eng, J. & Rohatgi, R. Reporting of estimated GFR in the primary care clinic. Am. J. Kidney Dis. 49, 634–641 (2007).
Fox, C. H., Swanson, A., Kahn, L. S., Glaser, K. & Murray, B. M. Improving chronic kidney disease care in primary care practices: an upstate New York practice-based research network (UNYNET) study. J. Am. Board. Fam. Med. 21, 522–530 (2008).
Cortés-Sanabria, L. et al. Improving care of patients with diabetes and CKD: a pilot study for a cluster-randomized trial. Am. J. Kidney Dis. 51, 777–788 (2008).
Wentworth, A. L., Fox, C. H., Kahn, L. S., Glaser, K. & Cadzow, R. Two years after a quality improvement intervention for chronic kidney disease care in a primary care office. Am. J. Med. Qual. 26, 200–205 (2011).
Peralta, C. A. et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J. Am. Soc. Nephrol. 22, 147–155 (2011).
Peralta, C. A. et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA 305, 1545–1552 (2011).
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E. & Hsu, C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351, 1296–1305 (2004).
Brantsma, A. H. et al. Cardiovascular and renal outcome in subjects with K/DOQI stage 1–3 chronic kidney disease: the importance of urinary albumin excretion. Nephrol. Dial. Transplant. 23, 3851–3858 (2008).
Hallan, S. I. et al. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J. Am. Soc. Nephrol. 20, 1069–1077 (2009).
Hemmelgarn, B. R. et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 303, 423–429 (2010).
Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375, 2073–2081 (2010).
Astor, B. C. et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 79, 1331–1340 (2011).
Gansevoort, R. T. et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes in both general and high-risk populations. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. doi:10.1038/ki.2010.531.
Foley, R. N., Parfrey, P. S. & Sarnak, M. J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 32 (5 Suppl. 3), S112–S119 (1998).
Sarnak, M. J. et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 108, 2154–2169 (2003).
Landray, M. J. et al. Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study. Am. J. Kidney Dis. 56, 1082–1094 (2010).
Keane, W. F. et al. Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL Study. Clin. J. Am. Soc. Nephrol. 1, 761–767 (2006).
Wakai, K. et al. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. Nephrol. Dial. Transplant. 21, 2800–2808 (2006).
Kent, D. M. et al. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J. Am. Soc. Nephrol. 18, 1959–1965 (2007).
Johnson, E. S., Thorp, M. L., Platt, R. W. & Smith, D. H. Predicting the risk of dialysis and transplant among patients with CKD: a retrospective cohort study. Am. J. Kidney Dis. 52, 653–660 (2008).
Levin, A., Djurdjev, O., Beaulieu, M. & Er, L. Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. Am. J. Kidney Dis. 52, 661–671 (2008).
Hsu, C. Y., Iribarren, C., McCulloch, C. E., Darbinian, J. & Go, A. S. Risk factors for end-stage renal disease. 25-year follow-up. Arch. Intern. Med. 169, 342–350 (2009).
Bash, L. D., Astor, B. C. & Coresh, J. Risk of incident ESRD: a comprehensive look at cardiovascular risk factors and 17 years of follow-up in the Atherosclerosis Risk in Communities (ARIC) Study. Am. J. Kidney Dis. 55, 31–41 (2010).
Tangri, N. et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA 305, 1553–1559 (2011).
John, R., Webb, M., Young, A. & Stevens, P. E. Unreferred chronic kidney disease: a longitudinal study. Am. J. Kidney Dis. 43, 825–835 (2004).
Noble, E. et al. The impact of automated eGFR reporting and education on nephrology service referrals. Nephrol. Dial. Transplant, 23, 3845–3850 (2008).
Hobbs, H. et al. Referral patterns to renal services: what has changed in the past 4 years? Nephrol. Dial. Transplant. 24, 3411–3419 (2009).
BC Renal Agency. At a glance: 2010 BC Renal Agency scorecard [online], (2010).
The Renal Association. The UK eCKD Guide [online], (2006).
Levin, A. et al. Guidelines for the management of chronic kidney disease [online], (2008).
CARI: caring for Australians with renal impairment. Chronic kidney disease guidelines: prevention of progression of kidney disease [online], (2006).
Scottish Intercollegiate Guidelines Network. Diagnosis and management of chronic kidney disease: a national clinical guideline [online], (2008).
Fox, C. H., Brooks, A., Zayas, L. E., McClellan, W. & Murray, B. Primary care physicians' knowledge and practice patterns in the treatment of chronic kidney disease: an upstate New York practice-based research network (UNYNET) study. J. Am. Board. Fam. Med. 19, 54–61 (2006).
Richards, N. et al. Primary care-based disease management of chronic kidney disease (CKD), based on estimated glomerular filtration rate (eGFR) reporting, improves patient outcomes. Nephrol. Dial. Transplant. 23, 549–555 (2008).
James, M. T. et al. Glomerular filtration rate, proteinuria, and the incidence and consequences of acute kidney injury: a cohort study. Lancet 376, 2096–2103 (2010).
Triverio, P. A. et al. Long-term prognosis after acute kidney injury requiring renal replacement therapy. Nephrol. Dial. Transplant. 24, 2186–2189 (2009).
Coca, S. G., Yusuf, B., Shlipak, M. G., Garg, A. X. & Parikh, C. R. Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am. J. Kidney Dis. 53, 961–973 (2009).
Glassock, R. J. & Winearls, C. Diagnosing chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 19, 123–128 (2010).
Levey, A. S. et al. The definition, classification and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. doi:10.1038/ki.2010.483.
Drey, N., Roderick, P., Mullee, M. & Rogerson, M. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Am. J. Kidney Dis. 42, 677–684 (2003).
Keith, D. S., Nichols, G. A., Gullion, C. M., Brown, J. B. & Smith, D. H. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch. Intern. Med. 164, 659–663 (2004).
Hemmelgarn, B. R. et al. Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int. 69, 2155–2161 (2006).
Orlando, L. A., Owen, W. F. & Matchar, D. B. Relationship between nephrologist care and progression of chronic kidney disease. N. C. Med. J. 68, 9–16 (2007).
Levin, A. et al. Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter. Am. J. Kidney Dis. 38, 1398–1407 (2001).
Evans, M. et al. The natural history of chronic renal failure: results from an unselected, population-based, inception cohort in Sweden. Am. J. Kidney Dis. 46, 863–870 (2005).
Eriksen, B. O. & Ingebretsen, O. C. The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. Kidney Int. 69, 375–382 (2006).
Hoefield, R. A. et al. Factors associated with kidney disease progression and mortality in a referred CKD population. Am. J. Kidney Dis. 56, 1072–1081 (2010).
Rossing, K. et al. Progression of nephropathy in type 2 diabetic patients. Kidney Int. 66, 1596–1605 (2004).
Tseng, C. L. et al. Survival benefit of nephrologic care in patients with diabetes mellitus and chronic kidney disease. Arch. Intern. Med. 168, 55–62 (2008).
Garg, A. X., Mamdani, M., Juurlink, D. N. & van Walraven, C. for the Network of Eastern Ontario Medical Laboratories (NEO-MeL). Identifying individuals with a reduced GFR using ambulatory laboratory database surveillance. J. Am. Soc. Nephrol. 16, 1433–1439 (2005).
Aghaie-Jaladerany, H., Cowell, D. & Geddes, C. C. The early impact of the United Kingdom Chronic Kidney Disease (CKD) guidelines on the number of new attendances at renal clinics. Scott. Med. J. 52, 28–31 (2007).
Jain, A. K. et al. When laboratories report estimated glomerular filtration rates in addition to serum creatinines, nephrology consults increase. Kidney Int. 76, 318–323 (2009).
Hemmelgarn, B. R. et al. Nephrology visits and health care resource use before and after reporting estimated glomerular filtration rate. JAMA 303, 1151–1158 (2010).
Samaniego, M. D. Promoting pre-emptive or early kidney transplantation. Nephrol. News Issues 23, 54–55 (2009).
James, M. T., Hemmelgarn, B. R. & Tonelli, M. Early recognition and prevention of chronic kidney disease. Lancet 375, 1296–1309 (2010).
Kramer, A. et al. An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006. Nephrol. Dial. Transplant. 24, 3557–3566 (2009).
Udayaraj, U. P. et al. Socio-economic status, ethnicity and geographical variations in acceptance rates for renal replacement therapy in England and Wales: an ecological study. J. Epidemiol. Community Health 64, 535–541 (2010).
United States Renal Data System. 2010 Annual Data Report: Volume two: Atlas of End Stage Renal Disease: Chapter 12: International Comparisons [online], (2010).
Donovan, K., Ford D, van Schalkwyk, D. & Ansell, D. Chapter 16 of the 12th Annual Report of the UK Renal Registry: International Comparisons with the UK RRT Programme [online], (2009).
Hou, S. H., Bushinsky, D. A., Wish, J. B., Cohen, J. J. & Harrington, J. T. Hospital-acquired renal insufficiency: a prospective study. Am. J. Med. 74, 243–248 (1983).
Hoste, E. A. et al. Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity, and outcome. J. Am. Soc. Nephrol. 14, 1022–1030 (2003).
Leblanc, M. et al. Risk factors for acute renal failure: inherent and modifiable risks. Curr. Opin. Crit. Care 11, 533–536 (2005).
Uchino, S. et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 294, 813–818, (2005).
Mittalhenkle, A. et al. Cardiovascular risk factors and incident acute renal failure in older adults: the cardiovascular health study. Clin. J. Am. Soc. Nephrol. 3, 450–456 (2008).
Hsu, C. Y. et al. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int. 74, 101–107 (2008).
Ishani, A. et al. Acute kidney injury increases risk of ESRD among elderly. J. Am. Soc. Nephrol. 20, 223–228 (2009).
Okusa, M. D., Chertow, G. M., Portilla, D. for the Acute Kidney Advisory Group of the American Society of Nephrology. The nexus of acute kidney injury, chronic cidney disease, and World Kidney Day 2009. Clin. J. Am. Soc. Nephrol. 4, 520–522 (2009).
Lafrance, J. P., Djurdjev, O. & Levin, A. Incidence and outcomes of acute kidney injury in a referred chronic kidney disease cohort. Nephrol. Dial. Transplant. 25, 2203–2209 (2010).
Grams, M. E. et al. Albuminuria and estimated glomerular filtration rate independently associate with acute kidney injury. J. Am. Soc. Nephrol. 21, 1757–1764 (2010).
Huerta, C., Castellsague, J., Varas-Lorenzo, C. & García Rodríguez, L. A. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am. J. Kidney Dis. 45, 531–539 (2005).
Drueke, T. B. & Massy, Z. A. Atherosclerosis in CKD: differences from the general population. Nat. Rev. Nephrol. 6, 723–735 (2010).
Kidney Disease Improving Global Outcomes. KDIGO Controversies Conference: cardiovascular disease in chronic kidney disease [online], (2010).
Das, M., Aronow, W. S., McClung, J. A. & Belkin, R. N. Increased prevalence of coronary artery disease, silent myocardial ischemia, complex ventricular arrhythmias, atrial fibrillation, left ventricular hypertrophy, mitral annular calcium, and aortic valve calcium in patients with chronic renal insufficiency. Cardiol. Rev. 14, 14–17 (2006).
Mann, J. F., Gerstein, H. C., Pogue, J., Bosch, J. & Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann. Intern. Med. 134, 629–636 (2001).
Lewis, E. J. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851–860 (2001).
Anavekar, N. S. et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N. Engl. J. Med. 351, 1285–1295 (2004).
Tonelli, M. et al. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am. J. Kidney Dis. 37, 484–489 (2001).
Shlipak, M. G. et al. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann. Intern. Med. 137, 555–562 (2002).
Wright, R. S. et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann. Intern. Med. 137, 563–570 (2002).
Al Suwaidi, J. et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 106, 974–980 (2002).
Gibson, C. M. et al. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J. Am. Coll. Cardiol. 42, 1535–1543 (2003).
Ezekowitz, J. et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J. Am. Coll. Cardiol. 44, 1587–1592 (2004).
Keough-Ryan, T. M. et al. Outcomes of acute coronary syndrome in a large Canadian cohort: impact of chronic renal insufficiency, cardiac interventions, and anemia. Am. J. Kidney Dis. 46, 845–855 (2005).
Li, S., Foley, R. N. & Collins, A. J. Anemia and cardiovascular disease, hospitalization, end stage renal disease, and death in older patients with chronic kidney disease. Int. Urol. Nephrol. 37, 395–402 (2005).
Parikh, N. I. et al. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch. Intern. Med. 166, 1884–1891 (2006).
Rakhit, D. J. et al. Effect of aggressive risk factor modification on cardiac events and myocardial ischaemia in patients with chronic kidney disease. Heart 92, 1402–1408 (2006).
Isbel, N. M. et al. Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function. Am. Heart J. 151, 745–753 (2006).
Ahmed, A. et al. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am. J. Cardiol. 99, 393–398 (2007).
Berger, A. K., Duval, S. & Krumholz, H. M. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J. Am. Coll. Cardiol. 42, 201–208 (2003).
Chertow, G. M., Normand, S. L. & McNeil, B. J. “Renalism”: inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency. J. Am. Soc. Nephrol. 15, 2462–2468 (2004).
Winkelmayer, W. C. et al. Kidney function and use of recommended medications after myocardial infarction in elderly patients. Clin. J. Am. Soc. Nephrol. 1, 796–801 (2006).
Winkelmayer, W. C., Charytan, D. M., Levin, R. & Avorn, J. Poor short-term survival and low use of cardiovascular medications in elderly dialysis patients after acute myocardial infarction. Am. J. Kidney Dis. 47, 301–308 (2006).
Erdmann, E., Lechat, P., Verkenne, P. & Wiemann, H. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur. J. Heart Fail. 3, 469–479 (2001).
Aoki, J. et al. Five year clinical effect of coronary stenting and coronary artery bypass grafting in renal insufficient patients with multivessel coronary artery disease: insights from ARTS trial. Eur. Heart J. 26, 1488–1493 (2005).
Ix, J. H. et al. Association of chronic kidney disease with clinical outcomes after coronary revascularization: the Arterial Revascularization Therapies Study (ARTS). Am. Heart J. 149, 512–519 (2005).
Coca, S. G., Krumholz, H. M., Garg, A. X. & Parikh, C. R. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 296, 1377–1384 (2006).
Ronco, C. et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur. Heart J. 31, 703–711 (2010).
Baigent, C. et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet doi: 10.1016/S0140-6736(11)60739-3
Szummer, K. et al. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation 120, 851–858 (2009).
Hoy, W., Baker, P. R., Kelly, A. M. & Wang, Z. Reducing premature death and renal failure in Australian aboriginals. a community-based cardiovascular and renal protective program. Med. J. Aust. 172, 473–478 (2000).
Iseki, K. Screening for renal disease—what can be learned from Okinawa experience. Nephrol. Dial. Transplant. 21, 839–843 (2006).
Iseki, K., Ikemiya, Y. & Fukiyama, K. Risk factors of end-stage renal disease and serum creatinine in a community-based mass screening. Kidney Int. 51, 850–854 (1997).
Yamagata, K. et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin. Exp. Nephrol. 12, 1–8 (2008).
Tobe, S. W. et al. Effect of nurse-directed hypertension treatment among First Nations people with existing hypertension and diabetes mellitus: the Diabetes Risk Evaluation and Microalbuminuria (DREAM 3) randomized controlled trial. CMAJ 174, 1267–1271 (2006).
Pylypchuk, G. et al. Diabetes risk evaluation and microalbuminuria (DREAM) studies: ten years of participatory research with a First Nation's home and community model for type 2 diabetes care in Northern Saskatchewan. Int. J. Circumpolar Health 67, 190–202 (2008).
Wanner, C. et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353, 238–248 (2005).
Drueke, T. B. et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med. 355, 2071–2084 (2006).
Singh, A. K. et al. Correction of anemia with epoetin alfa in chronic kidney diease. N. Engl. J. Med. 355, 2085–2098 (2006).
Pfeffer, M. A. et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 361, 2019–2032 (2009).
Fellström, B. C. et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 360, 1395–1407 (2009).
A. Levin and P. E. Stevens are co-Chairs of the Working Group for the Development of Chronic Kidney Disease Guidelines, which is sponsored by Kidney Disease: Improving Global Outcomes (KDIGO).
The authors declare no competing financial interests.
About this article
Cite this article
Levin, A., Stevens, P. Early detection of CKD: the benefits, limitations and effects on prognosis. Nat Rev Nephrol 7, 446–457 (2011). https://doi.org/10.1038/nrneph.2011.86
BMC Nephrology (2017)
Intensive Care Medicine (2017)
Nature Reviews Nephrology (2015)
Intensive Care Medicine (2015)
The eGFR-C study: accuracy of glomerular filtration rate (GFR) estimation using creatinine and cystatin C and albuminuria for monitoring disease progression in patients with stage 3 chronic kidney disease - prospective longitudinal study in a multiethnic population
BMC Nephrology (2014)